A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

Shares of BriaCell Therapeutics Corp. (NASDAQ: BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with B ...

Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Multiple studies suggest that making mindful choices about your diet, exercise, and stress management can help lower your ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

2. Ovarian Cancer: Research indicates that a woman's chance of developing ovarian cancer may be influenced by hormonal ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...